Work

160P Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results

Year: 2024

Type: article

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100789

Authors: D. Vaitiekus, E. Juozaityte, L. Puzauskienė, S. Tulyte, L. Gatijatullin, M. Platten, I. Poschke, I. Hulsmeyer, A. Kuhn, A. Aranguren, H. Lubenau, H. Fontenelle, B. Simovski, Y. Yamashita, C. Chaput, A. Meiser, V. Urbonas

Institutions: Lithuanian University of Health Sciences, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Vilnius University, Vilnius University Hospital Santariskiu Klinikos, National Cancer Institute, National Center for Tumor Diseases, NEC (Japan), NEC (Germany)

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170

OpenAlex ID: W4405374366

FWCI: 0.146

Cites:

Cited by: 1

Related to: 10